|Systematic (IUPAC) name|
|Biological half-life||5.2 ± 1.7 (range 0.4 to 5.5) minutes|
|ATC code||P01BA06 (WHO)|
|Molar mass||355.861 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Amodiaquine has been shown to be more effective than chloroquine in treating CRPF (chloroquine-resistant Plasmodium falciparum) malaria infections and may afford more protection than chloroquine when used as weekly prophylaxis. Amodiaquine, like chloroquine, is generally well tolerated. Although licensed, this drug is not marketed in the United States but is widely available in Africa. Its use, therefore, is probably more practicable in long-term visitors and persons who will reside in Africa.
Amodiaquine is a histamine N-methyltransferase inhibitor.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|50px||This antiinfective drug article is a stub. You can help ssf by expanding it.|